MGX Metagenomi Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: MGX

Price (delayed)

$1.13

Market cap

$42.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$36.99M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 30
Highlights
The debt has declined by 12% year-on-year and by 3.7% since the previous quarter
The revenue has dropped by 60% year-on-year and by 39% since the previous quarter
The company's gross profit has shrunk by 60% YoY and by 39% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.metagenomi.co
Peers: ILMN NTLA CRSP EDIT

Key stats

What are the main financial stats of MGX

MGX stock price

How has the Metagenomi stock price performed over time
Intraday
-0.88%
1 week
-1.74%
1 month
-8.13%
1 year
-48.17%
YTD
-30.25%
QTD
-5.04%

Financial performance

How have Metagenomi's revenue and profit performed over time
Revenue
$13.56M
Gross profit
$13.56M
Operating income
-$100.57M
Net income
-$93.46M
Gross margin
100%
Net margin
-689.2%
Metagenomi's operating margin has shrunk by 173% YoY and by 78% QoQ
The net margin has dropped by 167% year-on-year and by 79% since the previous quarter
The revenue has dropped by 60% year-on-year and by 39% since the previous quarter
The company's gross profit has shrunk by 60% YoY and by 39% QoQ

Price vs fundamentals

How does MGX's price correlate with its fundamentals

Growth

What is Metagenomi's growth rate over time

Valuation

What is Metagenomi stock price valuation
P/E
N/A
P/B
0.38
P/S
3.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.73
Metagenomi's EPS has decreased by 8% from the previous quarter and by 6% YoY
The equity has declined by 43% year-on-year and by 18% since the previous quarter
The P/B is 5% lower than the last 4 quarters average of 0.4
The revenue has dropped by 60% year-on-year and by 39% since the previous quarter
MGX's price to sales (P/S) is 17% higher than its last 4 quarters average of 2.7

Efficiency

How efficient is Metagenomi business performance
Metagenomi's ROS has plunged by 158% YoY and by 79% from the previous quarter
Metagenomi's ROE has plunged by 64% YoY and by 24% from the previous quarter
The ROIC has plunged by 61% YoY and by 25% from the previous quarter
MGX's ROA has shrunk by 60% YoY and by 22% QoQ

Dividends

What is MGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGX.

Financial health

How did Metagenomi financials performed over time
The total assets is 184% more than the total liabilities
The total assets has contracted by 36% YoY and by 12% from the previous quarter
MGX's current ratio is down by 30% since the previous quarter and by 29% year-on-year
The debt is 66% smaller than the equity
The company's debt to equity has surged by 55% YoY and by 21% QoQ
The equity has declined by 43% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.